Association between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma.
Gujarathi R, Rodman C, Bansal V, Belmont E, Setia N, Alpert L, Hart J, Moller M, Eng O, Lee G, Chin J, Amin M, Polite B, Liao C, Turaga K, Shergill A. Association between activating GNAS mutations and outcomes with chemotherapy in metastatic appendiceal adenocarcinoma. Journal Of Clinical Oncology 2024, 42: 4179-4179. DOI: 10.1200/jco.2024.42.16_suppl.4179.Peer-Reviewed Original ResearchAppendiceal adenocarcinomaGNAS mutationsOverall survivalActivating GNAS mutationsGNAS statusSynchronous metastasesPredictive biomarkersMetastatic disease treated with chemotherapyCox proportional hazards regression analysisGNAS activating mutationsMetastatic appendiceal adenocarcinomaProportional hazards regression analysisEvent free survivalEvent-free survivalMedian Follow-UpHazards regression analysisFree survivalRadiographic recurrenceFavorable diseaseAA patientsSurvival benefitAssociated with differential outcomesClinicopathological characteristicsClinicopathological featuresNo significant difference
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply